Liraglutide

Liraglutide is an engineered peptide that activates receptors for glucagon-like peptide-1 (GLP-1). It has been investigated for effects on glucose regulation, obesity-related outcomes, and cardiovascular health.

GLP-1 is a naturally occurring hormone involved in coordinating metabolic responses to food. Its signaling contributes to glucose homeostasis and the regulation of hunger and satiety.

Liraglutide engages the GLP-1 receptor, reproducing aspects of signaling normally initiated by the endogenous hormone. Mechanistic research examines how this receptor activity influences appetite-related processes and glucose regulation.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 04 · Clinical evidence

Controlled clinical research supports specific, narrowly defined conclusions.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents liraglutide as a synthetic hormone analogue developed for diabetes and excess-weight management. It attributes potential metabolic and cardiovascular advantages to GLP-1 receptor signaling, but the extracted material provides no supporting references or study details. The guide also describes gastrointestinal adverse effects and less frequent safety concerns.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The extracted notes do not establish the magnitude, consistency, or population-specific relevance of the reported outcomes. The relevance to humans of the thyroid tumor findings described in animals cannot be determined from this material.

The guide lists nausea, loose stools, and abdominal discomfort, alongside concerns about pancreatic inflammation, gallbladder disorders, and thyroid tumors observed in animal research. It also highlights the possibility of low blood glucose, particularly with certain other diabetes medicines. Safety data are limited in the supplied source material, which is insufficient for an individual risk assessment; this information is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Liraglutide weight loss diabetes management”
• “Liraglutide GLP-1 agonise clinical study”
• “Liraglutide clinical trials in obesity”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN